UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2016
__________
Commission File Number: 001-37891
AC IMMUNE SA
(Exact name of registrant as specified in its charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Item 7.01 Regulation FD Disclosure.
AC Immune SA (“AC Immune”) has updated its investor presentation with recent data presented by its partner Genentech, a member of the Roche group, at the 9th Clinical Trials on Alzheimer’s Disease Conference (CTAD) in San Diego. The updated investor presentation and informational poster that summarizes the data are attached hereto as Exhibit 99.1 and 99.2, respectively. From time to time, AC Immune will use this updated presentation and the informational poster in conversations with investors, analysts and others.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description |
| 99.1 | AC Immune SA Investor Presentation |
| 99.2 | Informational Poster |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | AC IMMUNE SA |
| | | |
| | | |
| | | | By: | /s/ Andrea Pfeifer |
| | | | | Name: | Andrea Pfeifer |
| | | | | Title: | Chief Executive Officer |
| | | | By: | /s/ Martin Velasco |
| | | | | Name: | Martin Velasco |
| | | | | Title: | Chairman |
Date: December 15, 2016
EXHIBIT INDEX
| Exhibit Number | Description |
| 99.1 | AC Immune SA Investor Presentation |
| 99.2 | Informational Poster |
